Subjects:
• Global Regulatory Requirements and New Trends
• General Considerations for Clinical Trials
• Global Development Plan
• Target Product Profile – Global Focus
• Clinical Protocol
• Clinical Efficacy, Safety and Benefit-Risk
• Endpoints: Treatment Monitoring
• Clinical Study
• Integrated Clinical Study Report (ICH E3)
• Pharmacokinetic and Pharmacodynamics
• Special Populations
• Interactions and Drug/Drug Interactions
• Early Clinical Development
• Drug Safety – from Non-clinical to Post-approval Activities
• Statistics in Clinical Trials
• Studies in Paediatric Population
• Clinical Summaries and Clinical Overview
• Risk Management in a Pharmaceutical Company
• Interactions with Health Authorities
• Pharmacovigilance/Post-Marketing Risk Assessment
• Post-approval Studies
Lecturers:
• Sheelagh Corcoran, Training Consultant, UK
• Anders Dejgaard, Corporate Vice President, Chief Medical Officer for Modern Insulin, Denmark
• Linda Donnini, PAREXEL, Medical Writing Services, PAREXEL, UK
• Steffen Thirstrup, Chief Medical Officer, Head of Department, Danish Medicines Agency, Denmark
• Steven B. Johnson, Vice President, Regulatory Affairs, Novo Nordisk A/S, USA
• Thanos Konstantakopoulos, PhD, Senior Regulatory Associate - European Regulatory Affairs, Lilly, United Kingdom
• Ida Holme Håkonsson, Head of Section, MD, PV Science, LEO Pharma A/S, Denmark
• Sinan Bardakci Sarac, Assessor, Consumer Safety Division, Danish Medicines Agency, Denmark
• Vibeke Bjerregaard, Regulatory Product Manager, Novo Nordisk A/S, Denmark
• Dr. Birka Lehmann, Director and Professor, BfArM - Federal Institute for Drugs and Medical Devices, Germany
• Martin Schultz, International Clinical Trial Leader, Genmab A/S, Denmark
•
Mark Ainsworth, Vice Chairman, Board of Registration, The Danish Medicines Agency and Consultant Gastroenterologist, Department of Gastroenterology, Copenhagen University Hospital at Herlev, Denmark
• Birgitte Søgaard, Head of Department, Clinical Pharmacology, H. Lundbeck A/S, Denmark
• Janet Wade, Senior Consultant, Exprimo, Sweden
• Nedjad Losic, Associate Director Statistics, Genmab A/S, Denmark
• Dr Malcolm Barratt-Johnson, Managing Partner, The BJ Partnership LLP, UK
• Torben Balchen, Director, DanTrials ApS, Denmark
• Marie Aavang Geist, Risk Management Specialist Pharmacovigilance, H. Lundbeck A/S, Denmark